MedTrace Logo

Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab

NCT01471691 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2015-04-29

Study results available
· View outcomes & findings →

Summary

This study examines two doses of Ranibizumab (0.5mg and 1.0mg) for the treatment of macular edema secondary to retinal vein occlusion in patients that have previously failed treatment with other macular edema treatments including bevacizumab.

Conditions

  • Branch Retinal Vein Occlusion
  • Central Retinal Vein Occlusion
  • Macular Edema

Interventions

DRUG

ranibizumab 0.5mg

Standard dose

DRUG

ranibizumab 1.0mg

High dose

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Hanscom, Thomas, M.D.

    lead INDIV

Principal Investigators

  • Thomas O'Hearn, MD · Thomas Hanscom AMC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01471691 on ClinicalTrials.gov